Feb 23,2022

Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities

Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced a partnership with Tilak Healthcare, a digital therapeutics company specializing in clinically validated medical mobile apps for chronic diseases. Under this new collaboration, both companies will combine Tilak’s OdySight Care mobile app with Voluntis’ Theraxium platform to offer a vision-screening solution for patients living with cancer. This new solution will give patients of Voluntis’ digital therapeutics platform access to OdySight Care and the possibility to measure their visual health anytime and anywhere. Once they have tested their vision using the OdySight Care application on their mobile device, patients will receive a clinically-validated visual acuity score in real time, providing them with medical advice and guidance relating to their ophthalmic health.

COLLABORATION PARTNERSHIP

#product & service

#dtx

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 31,2022

Carevive Partners with Datavant to Connect Carevive SMART Data™ and Advance Life Science Research

Carevive Systems (“Carevive”) the leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer, and Datavant, the leader in helping organizations securely connect health data, today announced a collaboration to de-identify and connect Carevive’s oncology patient experience data (SMART Data™) in order to support life sciences companies engaged in health economics and outcomes research, clinical development planning and post-market observational studies.

COLLABORATION PARTNERSHIP

#data & technology

#platform

#big data

View Analyst & Ambassador Comments
Go to original news
Mar 22,2022

OncoHealth™ Launches New Consumer Platform Bringing Digital Telehealth Services to People with Cancer

OncoHealth, the leading digital health company dedicated to oncology, unveiled today a new digital telehealth service for people with cancer. Iris™ by OncoHealth combines human-centered design, mobile technology, data, empathy, and specially trained oncology experts to deliver personalized, oncology-specific, 24×7 telehealth support to patients and their families facing cancer.

PRODUCT

#telehealth

View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

Project to Help NHS Digital Pathology Accelerate

The National Pathology Imaging Co-operative, NPIC, opens opportunities for NHS trusts throughout the country to digitise pathology and improve patient diagnoses, following new funding and expanding the usage of Sectra's digital pathology solution and VNA. A multi-million pound NHS initiative that already spans six trusts is expanding to help laboratories across different parts of the UK digitise their pathology services. Big wins are expected for patients and busy healthcare professionals.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

Machine Learning–Based Short-Term Mortality Prediction Models for Patients With Cancer Using Electronic Health Record Data: Systematic Review and Critical Appraisal

In the United States, national guidelines suggest that aggressive cancer care should be avoided in the final months of life. However, guideline compliance currently requires clinicians to make judgments based on their experience as to when a patient is nearing the end of their life. Machine learning (ML) algorithms may facilitate improved end-of-life care provision for patients with cancer by identifying patients at risk of short-term mortality.

CLINICAL STUDY

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Mar 11,2022

RefleXion raises $80M for biology-guided radiotherapy tech

RefleXion Medical announced that it closed an $80 million equity financing to support its therapeutic oncology technology. Hayward, California-based RefleXion develops biology-guided radiotherapy (BgRT) for all stages of cancer. The company designed BgRT to transform an injected radiotracer into a unified motion management solution that overcomes the technical limitations currently restricting radiotherapy use to one or two tumors. New investors joining the $80 million round were Ascension Ventures, Catalio Capital Management, Sixty Degree Capital and Hillenbrand Capital Partners.

FUNDING EQUITY FINANCE
View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

Illumina launches new genomic profiling test for cancer in Europe

Illumina (Nasdaq:ILMN) announced today that it launched its TruSight oncology test for assessing multiple tumor genes and biomarkers. San Diego-based Illumina’s CE-marked TruSight test, which will begin its global launch in Europe, assesses the tumor genes and biomarkers to reveal the specific molecular profile of a patient’s cancer, helping to inform precision medicine decisions. According to a news release, the new in vitro diagnostic (IVD) complete genome profiling (CGP) kit covers a wide array of current and emerging mutations and biomarkers, maximizing the chances of finding actionable biopsy information for each patient. Illumina said that its TruSight oncology test is the first IVD kit for PGC with CE mark based on DNA and RNA content

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 16,2022

Medtronic says data confirms effectiveness of AI-powered GI Genius in colonoscopy

Medtronic (NYSE:MDT) announced today that study results highlight the effectiveness of its GI Genius intelligent endoscopy module. The study, published in Gastroenterology, found that the use of GI Genius in conjunction with colonoscopy significantly decreases the miss rate (2x) of colorectal polyps and adenomas compared to standard colonoscopy. GI Genius uses AI to help detect colorectal polyps during colonoscopy to potentially prevent colorectal cancer.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Mar 25,2022

Roche, Bristol Myers team up to develop AI for clinical trials

The latest step in its mission to combine AI and digital pathology to improve cancer care will see Roche join forces with Bristol Myers Squibb. Alongside the Big Pharma, it’ll develop new algorithms that can be used in clinical trials to help develop highly specific drugs and more accurate companion diagnostics. To start, the partnership will focus on developing two digital pathology algorithms to help with analysis of Roche’s existing clinical trial assays.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 31,2022

Optellum wins CE mark for AI-powered early lung cancer diagnostic tech

Oxford, England-based Optellum designed the Virtual Nodule Clinic as a clinical decision-support tool for helping clinicians identify and track at-risk patients who present suspicious lung nodules that may or may not be cancerous. The platform received FDA 510(k) clearance in March 2021.

REGULATORY CE MARK

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY